Madhu Venkat, CEO of Natco Pharma Canada, highlights the company’s portfolio strategy, its strategic road map to be the first mover and become a leading generic supplier in oncology by 2020. He further illustrates that to be successful in Canada, it pays off to be a niche player and vertically integrated manufacturer.
The Canadian affiliate of Natco Pharma was created in 2012. What made 2012 a good moment for the company to venture into the Canadian environment?
"Canada is one of those markets where if you file a product dossier completely as per current regulations, you can count on timely approvals and reasonable transparency by the authorities."
